Innovative Biopsy Devices Identify Cancer Cells at its Early Stage
With the advancements of modern science, and emergence of bio-psycho-socio-therapeutic model, there has been a growing demand for obtaining accurate therapeutic results, say research analysts at Allied Market Research (AMR). Optimal therapeutic result with minimal damage is what many prominent players such as UAB focusing on, highlight AMR researchers. Earlier, oncologists depended greatly on sophisticated and complex imaging devices and biopsies to detect diseases such as cancer in symptomatic patients. In most cases, when detected the disease is often at an advanced stage, which makes it tougher to cure or treat. Therefore, to enhance the clinical results, scientists are concentrating on ways to detect cancer sooner. Such efforts have encouraged innovative discoveries in the biopsy devices market.
CT Guided Device Discovery Brings Hope for Radiology Department
There has been an increasing demand for a device that can aid Interventional radiologists to carry out “Computed Tomography (CT)” directed biopsy safely. In a recent incident a group of engineering students from the famous Sultan Qaboos University and medical specialists from the Oman Medical Specialty Board created history by inventing a similar CT guided device. Echoing their sentiments about the device the team said “We called our device the Painless CT-guided Biopsy Device.”
Computed Tomography guided biopsy is a procedure by which Interventional radiologists can obtain a sample of the tissues from a human body. The tissue sample is then tested in a histopathology laboratory to get the final diagnosis results. So far, the process was performed manually. Besides this, the traditional method also carried greater risk for medical practitioners and patients and is time-consuming. But, not anymore! The team behind this innovative equipment is determined to demonstrate it at various local conferences and international events and exhibitions. Such discoveries are expected to drive in huge investment towards R&D in the biopsy devices market.
Robotic Surgeon is here to Detect Your Cancer Cells
There has been a growing speculation about surgeons being assisted by robots to detect cancerous tissues. While many doubted the capability of these knives to sniff out the cancer cells, iKnife - an intelligent knife - shows its dexterity is beyond normal human potentiality. Developed by a group of scientists at “Imperial College London”, the device is undergoing clinical trials as a part of the institute’s plans to “roboticise” medical surgery.
iKnife can easily detect the smoke as it burns through human tissue. This enables doctors to identify if the cells are cancerous. The team behind the discovery explains that the optical biopsy device has the power to sniff the cancer cells, and is an imaging tool that overlays traditional x-ray and MRI images onto real – time images to guide surgeons. Guang-Zhong Yang, a professor and director at the reputed Hamlyn Centre, Imperial College said “We are entering a new age of precision surgery.” Yang added “We want to enhance surgeons with robots that give them almost superhuman powers to image and diagnose damaged tissues, and the dexterity to repair them.”
View all report related to medical device at: https://www.alliedmarketresearch.com/life-sciences/medical-devices-market-report
Promising Option for Prostate Cancer
Prostate cancer is one of the leading causes of death in men, especially in the United States. The condition has persuaded several scientists to work on finite element technology that could improve the precision of magnetic resonance-guided ultrasound biopsy. The solution emerged in the form of trans-rectal ultrasound-guided biopsy or TRUS. Scientists are planning on enhancing TRUS biopsies by image fusion, magnetic resonance guidance.
It is Now Possible to Cut Back On Melanoma Biopsy
Melanoma is the deadliest form of skin cancer in the world. The dangerous-looking moles on a patient’s face may look harmless, but it is impossible to say without performing an invasive surgical biopsy. But, today dermatologists have an access to the right tool. It all began when MelaFind, an optical scanner, was introduced to the biopsy device market players’ in 2013. This handheld device has been approved by the Food and Drug Association, particularly for multispectral analysis of human tissue morphology.
The device provides data, which a medical practitioner can use to identify whether or not to perform a biopsy. Here, the goal is to lower the count of patients who are left with biopsy scars. Such devices often eliminate the cost involved in unnecessary surgeries. The MelaFind device uses missile navigation techniques, initially paid for defense to scan the surface of any suspicious injury at about 10 electromagnetic wavelengths.
Today, intense competition mainly in the APAC women’s health equipment sector is driving the biopsy device market. In addition, this significant growth is assisted by the reproduction technology industry. The breast biopsy and breast imaging sector in countries including Japan and Australia have attracted many new players to the biopsy device market. Local hospitals such as the Vidant Medical Center located in Greenville are betting on advanced technologies on innovative lung biopsy device. Vidant became the first local hospital to use an advance biopsy device called CrossCountry for lung cancer in 2015. Commenting on the innovation Dr. Mark Bowling, an Interventional Pulmonology Director at the famous East Carolina University Brody School of Medicine, said “It’s a fact that close to half of all lung cancers happen outside of these airways. And that’s where the cross country device comes in.” He explained “The Cross Country device is a long narrow sheath that we navigate with, it goes outside of the airways, through the lung tissue until it reaches the area where the tumor or cancer is.”
Research Analyst at Allied Market Research
Deepa Tatkare has an experience of more than 3.5 years in market assessments and forecasts in healthcare & medical device industry. She is actively involved in providing critical insights on business research to clients with her subject matter expertize. Her profile includes planning, commissioning, and executing syndicate as well as customized research projects. She has successfully analyzed and presented data for studies related to medical devices, biotechnology, and pharmaceutical domains.
Developments in Biomarkers Market Answer Diagnosis Concerns
Radiopharmaceuticals Aim at Lowering Radiation for Staff & Drugs in a Facility